source
- Seaport and Hemab price IPOs as Avalyn soars on Nasdaq debutThree biotechnology companies announced the pricing of their initial public offerings between Thursday and Friday, collectively targeting more than $850 million in proceeds. Seaport Therapeutics a…
- Seaport Therapeutics jumps over 20% on Nasdaq debut as former Karuna team outlines CNS research plansSeaport Therapeutics began trading on Nasdaq on May 1, 2026, ringing the opening bell. Its shares surged more than 20% on the first day. The company’s leadership, including the CEO and CSO, highli…